These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 29875280)
41. Deep phylogeny of cancer drivers and compensatory mutations. Rochman ND; Wolf YI; Koonin EV Commun Biol; 2020 Oct; 3(1):551. PubMed ID: 33009502 [TBL] [Abstract][Full Text] [Related]
42. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer. Anoosha P; Huang LT; Sakthivel R; Karunagaran D; Gromiha MM Mutat Res; 2015 Oct; 780():24-34. PubMed ID: 26264175 [TBL] [Abstract][Full Text] [Related]
43. In silico saturation mutagenesis of cancer genes. Muiños F; Martínez-Jiménez F; Pich O; Gonzalez-Perez A; Lopez-Bigas N Nature; 2021 Aug; 596(7872):428-432. PubMed ID: 34321661 [TBL] [Abstract][Full Text] [Related]
44. Phase and context shape the function of composite oncogenic mutations. Gorelick AN; Sánchez-Rivera FJ; Cai Y; Bielski CM; Biederstedt E; Jonsson P; Richards AL; Vasan N; Penson AV; Friedman ND; Ho YJ; Baslan T; Bandlamudi C; Scaltriti M; Schultz N; Lowe SW; Reznik E; Taylor BS Nature; 2020 Jun; 582(7810):100-103. PubMed ID: 32461694 [TBL] [Abstract][Full Text] [Related]
45. Impact of deleterious passenger mutations on cancer progression. McFarland CD; Korolev KS; Kryukov GV; Sunyaev SR; Mirny LA Proc Natl Acad Sci U S A; 2013 Feb; 110(8):2910-5. PubMed ID: 23388632 [TBL] [Abstract][Full Text] [Related]
46. The mini-driver model of polygenic cancer evolution. Castro-Giner F; Ratcliffe P; Tomlinson I Nat Rev Cancer; 2015 Nov; 15(11):680-5. PubMed ID: 26456849 [TBL] [Abstract][Full Text] [Related]
47. Tumour suppressor gene mutations in humans and mice: parallels and contrasts. Hooper ML EMBO J; 1998 Dec; 17(23):6783-9. PubMed ID: 9843483 [TBL] [Abstract][Full Text] [Related]
48. Synergistic epistasis among cancer drivers can rescue early tumors from the accumulation of deleterious passengers. Alejandre C; Calle-Espinosa J; Iranzo J PLoS Comput Biol; 2024 Apr; 20(4):e1012081. PubMed ID: 38687804 [TBL] [Abstract][Full Text] [Related]
49. Efficient simulation under a population genetics model of carcinogenesis. Zhu T; Hu Y; Ma ZM; Zhang DX; Li T; Yang Z Bioinformatics; 2011 Mar; 27(6):837-43. PubMed ID: 21247938 [TBL] [Abstract][Full Text] [Related]
51. Effect of robustness on selection of a mutation-rate regulating gene. Ancliff M; Park JM Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Sep; 84(3 Pt 1):031925. PubMed ID: 22060421 [TBL] [Abstract][Full Text] [Related]
52. Topological transition of the parametric expression site of tumor suppressor inactivation as a marker evidence of environmental hormone-oriented cancer risk increase. Kodama M; Murakami M; Kodama T Int J Mol Med; 1999 Aug; 4(2):153-61. PubMed ID: 10402482 [TBL] [Abstract][Full Text] [Related]
53. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets. Anoosha P; Sakthivel R; Michael Gromiha M Biochim Biophys Acta; 2016 Feb; 1862(2):155-65. PubMed ID: 26581171 [TBL] [Abstract][Full Text] [Related]
55. Identification of constrained cancer driver genes based on mutation timing. Sakoparnig T; Fried P; Beerenwinkel N PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148 [TBL] [Abstract][Full Text] [Related]
56. Efficiency of carcinogenesis with and without a mutator mutation. Beckman RA; Loeb LA Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14140-5. PubMed ID: 16966602 [TBL] [Abstract][Full Text] [Related]